Rimonabant is sold under the trade name Accomplia. It is a cannabinoid receptor modulator that reduces appetite. Accomplia was never approved in the US but was approved in Europe. It has since been discontinued due to the increased occurrence of side effects with its use. The cannabinoid receptors are so named because they mediate the effects of cannabis (aka Marijuana). Cannabis is known to induce appetite whereas that blockade of this effect results in decreased appetite. Cannabis is also known to induce a state of relaxation so it is not too surprising that rimonabant caused an increase in anxiety, depression and suicide. There are also questions regarding the efficacy of rimonabant. Obese patients onl saw a decrease of 10 pounds over the course of one year. While this may sound great to someone looking to fit into a dress, for obese patients it is a drop on the bucket. Non-obese persons are likely to see little or no weight loss.